l4C1-or 8- [Phe-W] -bradykinin is precisely the same as that of blue dextran (MW > 2,000,000), a compound unlikely to leave the blood vessels during a single circulation. These results, plus the finding that lung tissue does not itself contain bradykinin or its peptide fragments, have been taken as evidence that inactivation occurs on or near the surface of vascular endothelial cells.
l4C1-or 8- [Phe-W] -bradykinin is precisely the same as that of blue dextran (MW > 2,000,000), a compound unlikely to leave the blood vessels during a single circulation. These results, plus the finding that lung tissue does not itself contain bradykinin or its peptide fragments, have been taken as evidence that inactivation occurs on or near the surface of vascular endothelial cells.
The relevant lung enzymes are either highly specific or are sequestered in a microenvironment capable of limiting access of substrate to enzyme. This formulation derives from the observations that all of the higher homologs of bradykinin are inactivated at rates slower than that of bradykinin. Whereas bradykinin is inactivated completely, up to 10 percent of Lys-bradykinin or bradykinin-Arg survives circulation through the lungs. Proportionately, larger fractions of Met-Lys-bradykinin and bradykinin-Ile-Tyr(S01) [Phyllokininl are spared. Two homologs, Lys-Lys-bradykinin and Polistes kinin, are not inactivated at all. The fact that each of the bradykinin homologs contains eight peptide bonds in common with bradykinin, yet is treated differently by the lung, favors the concept that the relevant enzymes are sequestered in an exclusive microen~ironment.~ There is a growing body of evidence which suggests that angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-PheHis-Leu) is converted to its more potent homolog, angiotensin I1 ( Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) , during passage through the pulmonary cir~ulation."~ The major finding in support of this hypothesis is that the venous effluent of lungs perfused with angiotensin I has a greater capacity to contract the rat colon and raise systemic conversion is a point not proved by bioassay. Recently we began a study to obtain chemical evidence of any such conversion. We found that 10-[Leu-14CI -angiotensin I is metabolized extensively during a single circulation through blood-free rat lung. More than half is metabolized to large C-terminal fragments, perhaps by an aminopeptidase. Approximately 20 percent is converted to angiotensin 11. Conversion occurs by removal of the C-terminal dipeptide, His-Leu, and not by the step-wise action of a carboxypeptidase. We were surprised to find that the majority of the biologic activity of the venous effluent is not accounted for by angiotensin 11. Most of the activity appears to be associated with a substance readily separated from the angiotensins by molecular sieve chromatography. Assuming ideal behavior, its molecular size is about one-third that of angiotensin 11. Whether the small biologically active substance is an active fragment of angiotensin I or an endogenous hormone of lung is not yet known.
There are striking similarities between the apparent means by which bradykinin and angiotensin I are metabolized: metabolism of either hormone is selective and does not depend on enzymes of blood or secretion of soluble hydrolase enzymes. Furthermore, lung does not retain either hormone or its metabolic products. These peculiar features suggest the possibility that the enzymes that inactivate bradykinin and convert angiotensin I to angiotensin I1 are situated on or near the surface of pulmonary endothelial cells." The venom of the Brazilian snake Bothrops iararaca contains a mixture of polypeptides, bradykinin potentiating factor, which potentiates the pharmacologic actions of bradykinin in vitro as well as in uivo. ' We have isolated nine biologically active peptides from the venom by ultrafiltration and column chromatographic procedures.2 The peptides contain 5-13 amino acid residues per molecule and have molecular weights in the range 600-1400. They have a high proline content (20-40 mole percent) and each has the cyclized form of glutamic acid (pyrrolidone carboxylic acid) as the amino terminus.
The structure of a biologically active pentapeptide was shown to be pyrrolidone-carboxyl-Lys-Trp-Ala-Pro. This peptide was synthetized by the solid phase method as proof of structure and several analogues were prepared in order to examine the relationship between structure and biologic activity on the isolated guinea pig ileum. The synthetic pentapeptide potentiated the activity of bradykinin two-fold at the same concentration bradykinin.4
Vane and coworkers"ave demonstrated that the pulmonary vascular bed plays the major role in the disappearance of circulating bradykinin and conversion of angiotensin I to angiotensin 11. Bradykinin potentiating factor inhibits the pulmonary disappearance of bradykinin" and the pulmonary conversion of angiotensin I to I1 in r;il;o.' Bradykinin potentiating factors and the purified peptides isolated from Bothrops jararaca venom". inhibit angiotensin converting enzyme in fractions derived from homogenized dog lung. We have used the blood pressure systemic response method10 to evaluate the effect of infusion of synthetic pyrrolidonecarboxylLys-Trp-Ala-Pro on these pulmonary processes in the rat. Infusion of the peptide at 100-200 ag/min inhibited the pulmonary conversion of angiotensin I to I1 and inhibited the pulmonary disappearance of bradykinin by more than 70 percent. However, the inhibitory effect of the peptide disappeared when the infusion was stopped. These infusion experiments illustrate the use of enzyme inhibitors to control the metabolism of these hormones in the pulmonary vascular bed. By using specific inhibitors of one or more of these enzymes it should be possible to demonstrate the participation of these hormones in various physiologic situations and perhaps to use these inhibitors as drugs to selectively control the flux of these peptides through certain pathways. Angiotensin-converting enzyme catalyzes the formation of the pressor octapeptide, angiotensin 11, from an inactive precursor, the decapeptide, angiotensin I. First isolated by Skeggs et all from horse plasma, the enzyme was later shown to be present at much higher and physiologically more significant concentration in the vascular beds of the lung.' The rapid conversion of angiotensin I in the pulmonary circulation and the observed particulate nature of the isolated enzyme, suggested a localization in or on the membrane of the capillary endothelial cel1,Qerhaps associated with specialized structures such as the pinocytotic vessicles discussed by Dr. Smith. The probable location of the angiotensinconverting enzyme on the vast area of membrane in direct contact with capillary blood, and the role of this enzyme in the metabolism of vasoactive peptides make it worthy of consideration for a possible physiologic or pathologic role in the lung, as well as in the cardiovascular system.
Purification and characterization of this important enzyme require the development of a simpler and more quantitative assay than the biologic assays which have been employed by most workers. A protected tripeptide, hippuryl-L-histidyl-L-leucine ( H H L ) , was found to be cleaved by the angiotensin-converting enzyme to yield histidylleucine and hippuric acid, the latter of which can 1, e extracted and quantitated by UV spectrophotometry at 228 nm. The specific activities of angiotensin-converting enzyme in various rat tissues assayed by this method were found to be in good agreement with the results obtained Ily Roth and coworkers;4 activity in lung was 30-fold greater than that of serum, and at least 5-fold -greater than the activity in any other tissue.
Substrate specificity studies employing a 70-fold purified angiotensin-converting enzyme from dog lung indicate that the enzyme is a carboxypeptidase that cleaves dipeptides rather than amino acids from the carboxyl terminus of polypeptides. The enzyme does not hydrolyze the methyl ester of HHL, hippuryl-L-histidine, or benzyloxycarbonyl-L-histidyl-L-leucine. In addition to catalyzing the formation of angiotensin 11, the enzyme can inactivate another important vasoactive peptide, bradykinin, by cleavage of the C-terminal phenylalanylarginine residue. It is uncertain what role, if any, this reaction might play in the pulmonary destruction of kinins, which was discussed by Drs. Ryan and Stewart.
Optimal activity of the enzyme in uitro is obtained at pH 8.3 in the presence of 300 mM NaC1. The apparent Michaelis constant for HHL was 2.6 mM, indicating that this tripeptide has a much lower affinity for the enzyme than angiotensin I. The angiotensin-converting enzyme is a metalloprotein which is activated 60 percent by addition of excess divalent cobalt ion, but not by other divalent metal ions. After removal of the naturally occurring metal ion by treatment with a high concentration of EDTA, followed by exhaustive dialysis, activity can be restored 160 percent by cobalt ion, 100 percent by zinc ion, or 40 percent by manganese ion. It seems probable that the enzyme is a zinc metalloprotein. It is inhibited by a great variety of metal-chelating or binding reagents and by heavy metal ions such as cadmium and mercury which probably exchange with the natural metal ion to
